Pmda - Pharmaceuticals and Medical Devices Agency

Jump to body

Navigation of each product type

Our recommended contents

Navigation of each product type

Our recommended contents

Home
Post-marketing Safety Measures
Information Services
Drugs
MHLW Pharmaceuticals and Medical Devices Safety Information
MHLW Pharmaceuticals and Medical Devices Safety Information (FY2020)

Here begins the text.

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2020)

FY 2020 (No.372-)

Japanese version issued on	No.	Table of contents	Posted on	PDF
June 16, 2020	373	Recent Trends in Cybersecurity Assurance of Medical Devices Important Safety Information Apalutamide Revision of Precautions (No. 313) Insulin human (genetical recombination) (vial preparations) Insulin aspart (genetical recombination) (vial preparations without description for continuous subcutaneous insulin infusion (CSII) therapy in the Dosage and Administration section) Insulin glargine (genetical recombination) (vial preparations) (and 7 others) List of Products Subject to Early Post-marketing Phase Vigilance	Jun 16, 2020	(Full text)
April 28, 2020	372	Genome Research on Drug-related Severe Cutaneous Adverse Reactions Important Safety Information Pembrolizumab (genetical recombination) Revision of Precautions (No. 312) Spiperone Timiperone Pipamperone hydrochloride (and 12 others) List of Products Subject to Early Post-marketing Phase Vigilance	Apr 28, 2020	(Full text)

Post-marketing Safety Measures

Pmda - Pharmaceuticals and Medical Devices Agency

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000047379

0

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2020)

/english/safety/info-services/drugs/medical-safety-information/0018.html

en